Alkermes plc (ALKS) exhibits 86.7% gross margins and 14.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 25.1x enterprise multiple and 4.8% implied options volatility.
Sustained 86.7% gross profitability converts into 17.2% operating margin and 14.0% ROIC, outpacing sector cost of capital.
ROIC: 14.0% // GM: 86.7%YoY revenue trajectory of -5.2% paired with 6.31% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -5.2% // FCF YLD: 6.31%Altman Z-Score of 8.03 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 8.03 // F-SCORE: 7/9Trading at 31.5x trailing P/E (29.3x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 31.5x // EV/EBITDA: 25.1xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $44.89 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 16.4% net margins.
NET MARGIN: 16.4% // D/E: 0.00x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ALKS & activate live FRED threshold breach alerts.